Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (3): 233-239.doi: 10.3969/j.issn.1000-6621.2021.03.008
• Original Articles • Previous Articles Next Articles
YAO Xu, WU Cheng-guo, GONG De-hua, YAO Yu-xia, ZHANG Can-you, XU Cai-hong, XIA Yin-yin, CHEN Hui, CHENG Jun(), ZHANG Hui(
)
Received:
2020-12-22
Online:
2021-03-10
Published:
2021-03-03
Contact:
CHENG Jun,ZHANG Hui
E-mail:chengjun@chinacdc.cn;zhanghui@chinacdc.cn
YAO Xu, WU Cheng-guo, GONG De-hua, YAO Yu-xia, ZHANG Can-you, XU Cai-hong, XIA Yin-yin, CHEN Hui, CHENG Jun, ZHANG Hui. Analysis of treatment completeness and its influencing factors of 12-week preventive therapy among close contacts of pulmonary tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2021, 43(3): 233-239. doi: 10.3969/j.issn.1000-6621.2021.03.008
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.03.008
基本特征 | 服药例数 | 构成比(%) | 基本特征 | 服药例数 | 构成比(%) |
---|---|---|---|---|---|
年龄(岁)a | 是否饮酒 | ||||
5~17 | 230 | 23.54 | 是 | 218 | 22.04 |
18~34 | 154 | 15.76 | 否 | 771 | 77.96 |
35~49 | 275 | 28.15 | 有无卡介苗接种卡痕 | ||
50~64 | 318 | 32.55 | 有 | 702 | 70.98 |
性别 | 无 | 287 | 29.02 | ||
男 | 400 | 40.44 | 是否与病原学阳性肺结核患者共同居住d | ||
女 | 589 | 59.56 | 是 | 648 | 65.59 |
职业b | 否 | 340 | 34.41 | ||
学生 | 269 | 27.23 | 负责预防性服药的机构 | ||
家务及待业 | 257 | 26.01 | 疾病预防控制中心 | 216 | 21.84 |
农、牧、渔(船)民 | 203 | 20.55 | 结核病防治所 | 182 | 18.40 |
其他 | 259 | 26.21 | 定点医院 | 591 | 59.76 |
文化程度c | 服药管理方式 | ||||
初中及以下 | 758 | 76.72 | 自我管理 | 464 | 46.92 |
高中及以上 | 230 | 23.28 | 家庭成员督导 | 201 | 20.32 |
是否吸烟 | 村医督导 | 324 | 32.76 | ||
是 | 135 | 13.65 | |||
否 | 854 | 86.35 |
影响因素 | 服药例数 | 完成服药例数 | 完成率(%) | χ2值 | P值 | |||
---|---|---|---|---|---|---|---|---|
性别 | 0.495 | 0.482 | ||||||
男 | 400 | 363 | 90.75 | |||||
女 | 589 | 542 | 92.02 | |||||
年龄(岁)a | 14.906 | 0.002 | ||||||
5~17 | 230 | 221 | 96.09 | |||||
18~34 | 154 | 142 | 92.21 | |||||
35~49 | 275 | 255 | 92.73 | |||||
50~64 | 318 | 277 | 87.11 | |||||
职业b | 11.543 | 0.001 | ||||||
学生 | 269 | 256 | 95.17 | |||||
家务及待业 | 257 | 233 | 90.66 | |||||
农、牧、渔(船)民 | 203 | 189 | 93.10 | |||||
其他 | 259 | 226 | 87.26 | |||||
影响因素 | 服药例数 | 完成服药例数 | 完成率(%) | χ2值 | P值 | |||
文化程度c | 0.152 | 0.697 | ||||||
初中及以下 | 758 | 695 | 91.69 | |||||
高中及以上 | 230 | 209 | 90.87 | |||||
是否吸烟 | 8.038 | 0.005 | ||||||
是 | 135 | 115 | 85.19 | |||||
否 | 854 | 790 | 92.51 | |||||
是否饮酒 | 4.241 | 0.039 | ||||||
是 | 218 | 192 | 88.07 | |||||
否 | 771 | 713 | 92.48 | |||||
有无卡介苗接种卡痕 | 0.719 | 0.396 | ||||||
有 | 702 | 639 | 91.03 | |||||
无 | 287 | 266 | 92.68 | |||||
是否与病原学阳性肺结核患者共同居住d | 0.879 | 0.348 | ||||||
是 | 648 | 589 | 90.90 | |||||
否 | 340 | 315 | 92.65 | |||||
负责预防性服药的机构 | 9.559 | 0.008 | ||||||
疾病预防控制中心 | 216 | 208 | 96.30 | |||||
结核病防治所 | 182 | 168 | 92.31 | |||||
定点医院 | 591 | 529 | 89.51 | |||||
服药管理方式 | 0.804 | 0.669 | ||||||
自我管理 | 464 | 428 | 92.24 | |||||
家庭成员督导 | 201 | 184 | 91.54 | |||||
村医督导 | 324 | 293 | 90.43 |
变量 | β值 | s | Wald χ2值 | P值 | OR(95%CI) |
---|---|---|---|---|---|
年龄(岁) | |||||
5~17 | - | - | - | - | 1.00 |
18~34 | 0.66 | 0.46 | 2.02 | 0.155 | 1.93(0.78~4.78) |
35~49 | 0.65 | 0.42 | 2.37 | 0.124 | 1.91(0.84~4.37) |
50~64 | 1.31 | 0.39 | 11.10 | <0.01 | 3.71(1.72~8.02) |
是否吸烟 | |||||
是 | 0.58 | 0.29 | 4.07 | 0.044 | 1.79(1.02~3.13) |
否 | - | - | - | - | 1.00 |
负责预防性服药的机构 | |||||
疾病预防控制中心 | - | - | - | - | 1.00 |
结核病防治所 | 0.98 | 0.50 | 3.84 | 0.051 | 2.67(0.99~7.15) |
定点医院 | 1.51 | 0.44 | 11.77 | <0.01 | 4.51(1.91~10.65) |
[1] |
Reichler MR, Khan A, Sterling TR, et al. Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis. J Infect Dis, 2018,218(6):1000-1008. doi: 10.1093/infdis/jiy265.
doi: 10.1093/infdis/jiy265 URL pmid: 29767733 |
[2] |
Park SY, Han S, Kim YM, et al. Risk of active tuberculosis development in contacts exposed to infectious tuberculosis in congregate settings in Korea. Sci Rep, 2020,10(1):1306. doi: 10.1038/s41598-020-57697-1.
URL pmid: 31992740 |
[3] |
Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med, 2014,161(6):419-428. doi: 10.7326/M14-1019.
doi: 10.7326/M14-1019 URL pmid: 25111745 |
[4] |
Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep, 2020,69(1):1-11. doi: 10.15585/mmwr.rr6901a1.
doi: 10.15585/mmwr.rr6901a1 URL pmid: 32053584 |
[5] | U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0. 2010-06-14. |
[6] | 孙振球. 医学统计学.3版. 北京: 人民卫生出版社, 2010. |
[7] |
Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011,365(23):2155-2166. doi: 10.1056/NEJMoa1104875.
URL pmid: 22150035 |
[8] | Huang YW, Yang SF, Yeh YP, et al. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan. Medicine (Baltimore), 2016,95(34):e4126. doi: 10.1097/MD.0000000000004126. |
[9] |
Schmit KM, Lobato MN, Lang SG, et al. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons. J Public Health Manag Pract, 2019,25(2):E1-E6. doi: 10.1097/PHH.0000000000000822.
doi: 10.1097/PHH.0000000000000822 URL pmid: 30024493 |
[10] | Villa S, Ferrarese M, Sotgiu G, et al. Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy. J Clin Med, 2019,9(1):101. doi: 10.3390/jcm9010101. |
[11] |
Onwubiko U, Wall K, Sales RM, et al. Using Directly Observed Therapy (DOT) for latent tuberculosis treatment-A hit or a miss? A propensity score analysis of treatment completion among 274 homeless adults in Fulton County, GA. PLoS One, 2019,14(6):e0218373. doi: 10.1371/journal.pone.0218373.
URL pmid: 31226132 |
[12] |
Lam CK, McGinnis Pilote K, Haque A, et al. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study. J Med Internet Res, 2018,20(11):e287. doi: 10.2196/jmir.9825.
doi: 10.2196/jmir.9825 URL pmid: 30459146 |
[13] |
Hirsch-Moverman Y, Colson PW, Bethel J, et al. Can a peer-based intervention impact adherence to the treatment of latent tuberculous infection? Int J Tuberc Lung Dis, 2013,17(9):1178-1185. doi: 10.5588/ijtld.12.0823.
URL pmid: 23928167 |
[14] |
Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018,52(6):1801470. doi: 10.1183/13993003.01470-2018.
doi: 10.1183/13993003.01470-2018 URL pmid: 30361241 |
[15] |
Sterling TR, Moro RN, Borisov AS, et al. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis, 2015,61(4):527-535. doi: 10.1093/cid/civ323.
doi: 10.1093/cid/civ323 URL pmid: 25904367 |
[16] |
Jo KW, Kim JS, Kwon HS, et al. Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers. Respir Med, 2019,158:42-48. doi: 10.1016/j.rmed.2019.10.005.
URL pmid: 31605920 |
[17] |
Sentís A, Vasconcelos P, Machado RS, et al. Failure to complete treatment for latent tuberculosis infection in Portugal, 2013—2017: geographic-, sociodemographic-, and medical-associated factors. Eur J Clin Microbiol Infect Dis, 2020,39(4):647-656. doi: 10.1007/s10096-019-03765-y.
doi: 10.1007/s10096-019-03765-y URL pmid: 31797155 |
[18] |
Plourde PJ, Basham CA, Derksen S, et al. Latent tuberculosis treatment completion rates from prescription drug administrative data. Can J Public Health, 2019,110(6):705-713. doi: 10.17269/s41997-019-00240-1.
doi: 10.17269/s41997-019-00240-1 URL pmid: 31297736 |
[19] |
Bennett RJ, Brodine S, Waalen J, et al. Prevalence and treatment of latent tuberculosis infection among newly arrived refugees in San Diego County, January 2010-October 2012. Am J Public Health, 2014,104(4):e95-e102. doi: 10.2105/AJPH.2013.301637.
URL pmid: 24524534 |
[20] |
Eastment MC, McClintock AH, McKinney CM, et al. Factors That Influence Treatment Completion for Latent Tuberculosis Infection. J Am Board Fam Med, 2017,30(4):520-527. doi: 10.3122/jabfm.2017.04.170070.
doi: 10.3122/jabfm.2017.04.170070 URL pmid: 28720633 |
[21] | 谷战英, 孙强, 姚静静. 定点医院模式实施前后结核病控制效果分析. 中国公共卫生, 2017,33(1):84-87. doi: 10.11847/zgggws2017-33-01-21. |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||